Inactive Instrument

GlaxoSmithKline plc Stock London S.E.

Equities

Pharmaceuticals

End-of-day quote London S.E.
- GBX - Intraday chart for GlaxoSmithKline plc

Financials

Sales 2024 * 31.64B 40.31B 54.93B Sales 2025 * 33.59B 42.8B 58.32B Capitalization 72.04B 91.78B 125B
Net income 2024 * 5.56B 7.08B 9.65B Net income 2025 * 6.5B 8.29B 11.29B EV / Sales 2024 * 2.67 x
Net Debt 2024 * 12.39B 15.79B 21.52B Net Debt 2025 * 8.95B 11.4B 15.54B EV / Sales 2025 * 2.41 x
P/E ratio 2024 *
12.8 x
P/E ratio 2025 *
11.1 x
Employees -
Yield 2024 *
3.45%
Yield 2025 *
3.57%
Free-Float 94.54%
More Fundamentals * Assessed data

Latest transcript on GlaxoSmithKline plc

Managers TitleAgeSince
Chief Executive Officer 55 10-04-30
Director of Finance/CFO 62 23-04-30
Compliance Officer - 95-07-31
Members of the board TitleAgeSince
Director of Finance/CFO 62 23-04-30
Chairman 66 19-08-31
Director/Board Member 62 17-12-31
More insiders
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company